BlueJay Therapeutics

Monoclonal Antibody, Small Molecule

Also Clin1 hepatitis D; BJT-628 Clin0 hepatitis B

BlueJay Therapeutics is developing therapeutics for the treatment of infectious diseases. In 2019, 296M people worldwide were living with hepatitis B. With decades of experience in HBV, virology, immunology and liver diseases, BlueJay is identifying and developing highly differentiated assets that offer the greatest therapeutic potential with the lowest risk for patients. BlueJay’s assets currently consist of antibody biologics and small molecules. BlueJay’s lead candidate, BJT-778, a best-in-class monoclonal antibody against hepatitis B surface antigen, recently received regulatory clearance to initiate clinical studies for patients with chronic hepatitis B. BJT-778 may help to reconstitute a patient’s antiviral immunity by neutralizing and clearing hepatitis B virions.